Orvasta (Atorvastatin)

Orvasta is a lipid‑lowering agent that acts on the cholesterol synthesis pathway. It is indicated for:

• Primary hypercholesterolaemia: reduces LDL‑C and total cholesterol levels.
• Mixed dyslipidaemia: lowers triglycerides and raises HDL‑C modestly.
• Primary prevention of cardiovascular events: helps reduce the risk of myocardial infarction, stroke and related vascular events in high‑risk patients.

• Atorvastatin competitively inhibits HMG‑CoA reductase, the key enzyme that catalyzes the conversion of HMG‑CoA to mevalonate, a precursor in hepatic cholesterol biosynthesis. By reducing intracellular cholesterol synthesis, hepatic cells up‑regulate LDL receptors, increasing clearance of circulating LDL particles and lowering plasma cholesterol concentrations.

Adverse reactions to Orvasta vary in frequency and severity.

Common Side Effects

• Myalgia or muscle aches.
• Elevated liver enzymes (ALT/AST).
• Gastrointestinal discomfort such as nausea or abdominal pain.
• Headache.
• Dizziness.

Serious or Rare Side Effects

• Rhabdomyolysis or severe muscle breakdown.
• Acute hepatic failure.
• Severe allergic reactions including angioedema.
• New‑onset diabetes mellitus.
• Persistent unexplained fatigue.

Before initiating therapy, clinicians should assess patient‑specific factors and monitor relevant parameters.

• Liver function: obtain baseline ALT/AST and repeat periodically.
• Muscle health: evaluate for myopathy symptoms, especially if combined with interacting drugs.
• Renal impairment: adjust monitoring in patients with severe kidney disease.
• Pregnancy and lactation: avoid use unless clearly indicated, as safety is not established.
• Drug interactions: review concomitant medications for potential statin interactions.
• Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Atorvastatin may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors).
• Gemfibrozil and other fibrates that increase risk of myopathy.
• Cyclosporine and certain antivirals (e.g., boce-boi.

Moderate Interaction ( Monitor Closely):

• Antacids containing aluminum or magnesium.
• Warfarin, requiring INR monitoring.
• Niacin, which may increase risk of liver enzyme elevation.
• Digoxin, as statins can modestly raise serum levels.
• St. St